TERT

TERT
National Center for Biotechnology Information, U.S. National Library of Medicine · Public domain · source
Name	TERT

TERT

Introduction

The reverse transcriptase catalytic subunit encoded by the telomerase complex is a pivotal enzyme in cellular replicative capacity, associated with replicative senescence and genomic stability. Its activity intersects with pathways studied by researchers at institutions such as Harvard University, National Institutes of Health, Stanford University, Massachusetts Institute of Technology, and University of Cambridge, and it is a focus of work appearing in venues like Nature (journal), Science (journal), and Cell (journal). Landmark figures in telomere research include Elizabeth Blackburn, Carol Greider, and Jack Szostak, whose Nobel Prize–winning studies linked telomerase function to chromosome end maintenance in model systems such as Saccharomyces cerevisiae, Caenorhabditis elegans, and Mus musculus.

Gene and Protein Structure

The gene encoding the catalytic subunit resides in vertebrate genomes with conserved domains analogous to reverse transcriptases characterized in studies from laboratories including Cold Spring Harbor Laboratory and Max Planck Society. Structural models combine motifs common to viral reverse transcriptases described for Human immunodeficiency virus 1 and polymerases investigated by groups at The Scripps Research Institute and European Molecular Biology Laboratory. Crystallography and cryo-electron microscopy contributions from teams at European Synchrotron Radiation Facility and Brookhaven National Laboratory revealed an active site with conserved aspartate residues and an RNA-binding domain that interfaces with the telomerase RNA component characterized in comparative analyses across Homo sapiens, Danio rerio, and Drosophila melanogaster. Mutations in conserved regions have been mapped in clinical cohorts studied at centers like Mayo Clinic and Cleveland Clinic.

Regulation and Expression

Transcriptional and post-transcriptional control of the catalytic subunit is modulated by transcription factors and signaling pathways frequently investigated at University of Oxford, Johns Hopkins University, and Columbia University. Promoter variants and somatic mutations were first identified in cohorts analyzed by consortia including The Cancer Genome Atlas and projects coordinated by International Agency for Research on Cancer. Regulatory influences include binding by factors such as c-Myc and interactions with chromatin modifiers studied in contexts involving p53, RB (protein), and components of the Wnt signaling pathway. Epigenetic landscapes mapped by groups at Broad Institute and Wellcome Trust Sanger Institute reveal methylation and histone modification patterns correlating with expression differences across tissues such as bone marrow, lung, liver, and skin (human).

Role in Telomere Maintenance and Cellular Aging

The catalytic subunit assembles with RNA and accessory proteins to elongate telomeric repeats, a process elucidated in classic experiments from laboratories tied to Yale University and Princeton University. Its activity counteracts replicative shortening first documented by studies at Cold Spring Harbor Laboratory and further explored in longevity research involving Calico Life Sciences collaborations. Telomere dynamics influence pathways involving ATM (gene), ATR (gene), and DNA damage response factors such as BRCA1 and BRCA2, with perturbations contributing to senescence phenotypes described in models like zebrafish and mouse knockout. Connections between telomerase action and aging were framed by epidemiological studies from institutions including University of California, San Francisco and Karolinska Institutet.

TERT in Cancer and Disease

Reactivation of the catalytic subunit is a hallmark in many malignancies characterized by mutational hotspots identified in studies coordinated by Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Research Center. Promoter mutations and aberrant expression are notable in melanoma, glioblastoma, hepatocellular carcinoma, bladder cancer, and thyroid cancer, with molecular epidemiology reported by groups in European Organisation for Research and Treatment of Cancer and American Association for Cancer Research. Germline variants and loss-of-function alterations associate with syndromes such as dyskeratosis congenita and bone marrow failure investigated at specialized centers like St. Jude Children's Research Hospital. Interactions with oncogenes and tumor suppressors—studied in cell lines from repositories like the American Type Culture Collection—link catalytic subunit dysregulation to genomic instability and therapeutic resistance observed in clinical trials conducted at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.

Clinical Applications and Therapeutic Targeting

Diagnostic and prognostic assays measuring catalytic subunit expression or promoter mutation status have been developed in collaboration between academic hospitals and biotechnology firms including Roche, Illumina, and Thermo Fisher Scientific. Therapeutic strategies targeting the enzyme include small-molecule inhibitors, antisense oligonucleotides, immunotherapies, and gene-editing approaches trialed through networks such as National Cancer Institute-sponsored consortia and biotech startups emerging from MIT and Stanford Biodesign. Clinical trials registered by cooperative groups including European Society for Medical Oncology and American Society of Clinical Oncology assess efficacy in cancers with high catalytic subunit activity, while regenerative medicine initiatives at institutions like Harvard Medical School and Karolinska Institutet explore controlled activation for degenerative disorders. Ethical and regulatory considerations involve agencies such as Food and Drug Administration and European Medicines Agency.

Category:Proteins